How well does Dacomitinib(Vizimpro) work?

VIZIMPRO demonstrated improved progression-free survival in patients with EGFR-positive metastatic NSCLC compared to gefitinib.

Clinical Effectiveness

In a clinical trial, patients treated with VIZIMPRO showed a median progression-free survival of 14.7 months, compared to 9.2 months for those on gefitinib. The overall response rate was 75%, with a median duration of response of 14.8 months, supporting its efficacy as a first-line treatment option.